Tvardi Therapeutics, Inc. (TVRD) - Total Assets
Based on the latest financial reports, Tvardi Therapeutics, Inc. (TVRD) holds total assets worth $39.02 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See TVRD book value for net asset value and shareholders' equity analysis.
Tvardi Therapeutics, Inc. - Total Assets Trend (2020–2024)
This chart illustrates how Tvardi Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data.
Tvardi Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Tvardi Therapeutics, Inc.'s total assets of $39.02 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 86.5% |
| Accounts Receivable | $4.50 Million | 10.3% |
| Inventory | $900.00K | 2.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Tvardi Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Tvardi Therapeutics, Inc..
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tvardi Therapeutics, Inc.'s current assets represent 100.0% of total assets in 2024, an increase from 71.9% in 2020.
- Cash Position: Cash and equivalents constituted 86.5% of total assets in 2024, up from 11.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 10.3% of total assets.
Tvardi Therapeutics, Inc. Competitors by Total Assets
Key competitors of Tvardi Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Tvardi Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.48 | 4.77 | 4.40 |
| Quick Ratio | 3.48 | 4.71 | 4.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $27.40 Million | $37.87 Million | $77.72 Million |
Tvardi Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Tvardi Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.67 |
| Asset Growth Rate (YoY) | 62.3% |
| Total Assets | $43.83 Million |
| Market Capitalization | $29.39 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tvardi Therapeutics, Inc.'s assets below their book value (0.67x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Tvardi Therapeutics, Inc.'s assets grew by 62.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tvardi Therapeutics, Inc. (2020–2024)
The table below shows the annual total assets of Tvardi Therapeutics, Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $43.83 Million | +62.32% |
| 2023-12-31 | $27.00 Million | -40.13% |
| 2022-12-31 | $45.10 Million | -81.75% |
| 2021-12-31 | $247.06 Million | -8.89% |
| 2020-12-31 | $271.16 Million | -- |
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on … Read more